Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
05/09/201713h00GlobeNewswire Inc.Summit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Select...NASDAQ:SMMTSummit Therapeutics Inc
31/08/201715h24Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
31/08/201713h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Second Quarter and Half Year Ended 31 July 2017 and Operational Progre...NASDAQ:SMMTSummit Therapeutics Inc
25/08/201715h30GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2017 on 31 August 2017NASDAQ:SMMTSummit Therapeutics Inc
03/08/201713h00GlobeNewswire Inc.Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceNASDAQ:SMMTSummit Therapeutics Inc
22/06/201723h44Dow Jones NewsADRs End Higher; Pharmaceuticals Trade ActivelyNASDAQ:SMMTSummit Therapeutics Inc
22/06/201717h21Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SMMTSummit Therapeutics Inc
22/06/201713h00GlobeNewswire Inc.Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society CongressNASDAQ:SMMTSummit Therapeutics Inc
15/06/201713h00GlobeNewswire Inc.Summit Therapeutics to Participate in JMP Securities Life Sciences ConferenceNASDAQ:SMMTSummit Therapeutics Inc
14/06/201713h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
13/06/201713h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2017 on 14 June 2017NASDAQ:SMMTSummit Therapeutics Inc
05/06/201713h00GlobeNewswire Inc.Summit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 2017NASDAQ:SMMTSummit Therapeutics Inc
23/05/201713h00GlobeNewswire Inc.Summit Announces Key Appointments to Strengthen Research and Development TeamNASDAQ:SMMTSummit Therapeutics Inc
15/05/201713h00GlobeNewswire Inc.Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMDNASDAQ:SMMTSummit Therapeutics Inc
29/04/201700h30GlobeNewswire Inc.Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Stati...NASDAQ:SMMTSummit Therapeutics Inc
30/03/201713h00GlobeNewswire Inc.Summit Therapeutics to Present at the Needham Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
29/03/201713h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Pr...NASDAQ:SMMTSummit Therapeutics Inc
27/03/201713h00GlobeNewswire Inc.Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients With DMDNASDAQ:SMMTSummit Therapeutics Inc
27/03/201713h00GlobeNewswire Inc.Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017NASDAQ:SMMTSummit Therapeutics Inc
15/03/201712h00GlobeNewswire Inc.Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
28/02/201713h00GlobeNewswire Inc.Summit Therapeutics Recognises 10th Annual Rare Disease DayNASDAQ:SMMTSummit Therapeutics Inc
14/02/201721h01Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SMMTSummit Therapeutics Inc
02/02/201713h00GlobeNewswire Inc.Summit Therapeutics to Participate in February Investor ConferencesNASDAQ:SMMTSummit Therapeutics Inc
01/02/201713h00GlobeNewswire Inc.Summit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory MeetingsNASDAQ:SMMTSummit Therapeutics Inc
18/01/201713h00GlobeNewswire Inc.Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & DevelopmentNASDAQ:SMMTSummit Therapeutics Inc
15/12/201613h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
13/12/201616h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2016 on 15 December 2016NASDAQ:SMMTSummit Therapeutics Inc
16/11/201613h00GlobeNewswire Inc.Summit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMDNASDAQ:SMMTSummit Therapeutics Inc
06/10/201613h00GlobeNewswire Inc.Summit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle SocietyNASDAQ:SMMTSummit Therapeutics Inc
04/10/201613h01GlobeNewswire Inc.Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for Europea...NASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

Delayed Upgrade Clock